問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of Urology

Division of Hematology & Oncology

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

邱宗傑Chiou, Tzeon-jye
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱宗傑

List

93Cases

2006-06-30 - 2007-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2009-09-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Suspended3Sites

2005-12-01 - 2007-11-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-04-30 - 2022-10-31

Phase II/III

A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Condition/Disease

    FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

  • Test Drug

    BAY 1163877

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-05-01 - 2018-12-19

Phase III

A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2

  • Condition/Disease

    indolent non-Hodgkin’s lymphoma (iNHL)

  • Test Drug

    BAY 80-6946

Participate Sites
2Sites

Terminated2Sites

2006-02-01 - 2007-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2006-09-01 - 2007-11-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-09-15 - 2016-12-31

Phase III

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.

  • Condition/Disease

    Colorectal cancer

  • Test Drug

    Nintedanib (BIBF 1120)

Participate Sites
5Sites

Terminated5Sites

2011-08-01 - 2014-01-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-03-06 - 2011-09-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB